[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.191.0. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
June 1961

Studies with Live Attenuated Measles-Virus Vaccine: III. Development of a Practical Method for Large-Scale Immunization

Author Affiliations

BALTIMORE; BALTIMORE
From the University of Maryland, School of Medicine, Baltimore, and Philips Roxane, Inc., St. Joseph, Mo.; Department of Medicine, Section of Infectious Diseases, University of Maryland, School of Medicine (Drs. McCrumb, Hornick, Kress, Schluederberg, Snyder and Mr. Bigbee); Associate Director of Biological Research, Philips Roxane, Inc. (Mr. Musser).

Am J Dis Child. 1961;101(6):708-712. doi:10.1001/archpedi.1961.04020070022005
Abstract

Introduction  Alteration of man's response to measles infection by parenteral administration of serum containing specific antibodies was first described by Nicolle and Conseil.1 Since 1918, several reports have confirmed the effectiveness of convalescent measles serum in the prevention of this disease as well as its usefulness in the therapy of measles during the preeruptive phase.2-5 Placental extracts were found to be at least as effective as human convalescent serum in aborting measles.6 Similarly, the concentration of antibody from normal human serum in Cohn's Fraction II, composed primarily of gamma globulin,7 yielded a product with potent measles-preventive activity. Evaluation of the protective and attenuating action of human gamma globulin in several large groups of susceptible children exposed to measles revealed the effectiveness of concentrated antibody.8,9 Furthermore, it was proposed on the basis of these studies that modification of measles could best be accomplished if globulin were

×